Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

escalating doses of TB-402. It is anticipated that the study will conclude by the end of 2010.

Patrik De Haes, CEO of ThromboGenics, commented on today's news "We are very excited about the start of the Phase II trial for TB-402. Our work to date suggests that this novel agent could represent a major advance in anti-coagulant therapy, given our expectation that it will cause fewer unwanted bleeding events and will require no monitoring of patients. This combined with its ability to be used as a "one-off" treatment could make TB-402 the anti-coagulant of choice to prevent DVT in patients undergoing surgery. Given the size of the market opportunity for TB-402 and the sales reach that will be needed to engage with the potential prescribers of TB-402, it is our intention to seek a partner to undertake the later stage development and commercialisation of this exciting new agent."

Svein Mathisen, CEO of BioInvent, also commented, "The initiation of this Phase II trial is another successful step forward in the clinical development of our antibody product development portfolio. TB-402 addresses a broad market and has potentially significant advantages over existing anti-coagulants. We are hopeful it will have application in a number of clinical settings."

About Deep Vein Thrombosis (DVT)

DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the U.S. alone, more than 350,000 individuals are affected by DVT or pulmonary embolism (PE) each year. Moreover, DVT and PE together may be responsible for more than 100,000 deaths in the U.S. each year.(1)

It is estimated that by 2015, 1.4 million patients will undergo knee replacement and 600,000 patients will undergo hip replacement in the U.S. if current trends persist.(2) Patients undergoing hip replacement or knee surgery are p
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- Blueprint Medicines (NASDAQ: BPMC ), a leader in ... defined diseases, today announced that Jeffrey Albers , ... the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August ... live webcast of the event will be available by ... at www.blueprintmedicines.com . An archived replay of the ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... On ... by inviting a diverse selection of entrepreneurs from across the United States to talk ... Jessica Richman is honored to be chosen to be among the attendees. , One ...
(Date:8/4/2015)... , Aug. 4, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: ... in China , today announced that ... second quarter, ended June 30, 2015, after market close ... conference call on Thursday, August 13, 2015, at 8:00 ... China Standard Time) to review the Company,s financial results ...
(Date:8/3/2015)...  ArroGen Group, an integrated advanced forensic solutions ... (FMID) technology Aug. 2-8 at the International Association ... Calif. FMID, a new ... agents, district attorneys and government agencies to build ... By analyzing chemical residues on fingerprints taken from ...
Breaking Biology Technology:White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2ArroGen Previews New Fingerprint Molecular Identification Technology 2
... in carbon-based nano-materials and devices have open ... Nanotechnology,s ability to manipulate carbon atoms and ... nanoscale materials and novel device structures with ... nanotechnology is anticipated to dramatically change every ...
... HILL, N.C., Jan. 12, 2011 Cempra Pharmaceuticals ... of solithromycin (CEM-101), the first fluoroketolide antibiotic, at ... Advanced Research and Development Authority (BARDA) industry day ...   Solithromycin is a clinical-stage fluoroketolide ...
... Cancer Research Center basic scientists Roger Brent, Ph.D., a ... and geneticist, have been elected fellows of the American ... as a fellow is an honor bestowed upon AAAS ... of the Hutchinson Center,s Basic Sciences Division, is being ...
Cached Biology Technology:Carbon-Based Nano-Materials and Devices Conference 2Carbon-Based Nano-Materials and Devices Conference 3Carbon-Based Nano-Materials and Devices Conference 4Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day 2Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day 3Roger Brent and Robert Eisenman Named AAAS Fellows 2Roger Brent and Robert Eisenman Named AAAS Fellows 3
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... -- Fingerprint Cards has received an order for ... the distributor World Peace Industrial Group (WPI), part of WPG ... Asia . Deliveries are planned to take place during ... smartphone manufacturers in Asia . The order ... guidance of approximately 2,200 MSEK for 2015. Jörgen ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC ... and finger-based biometric identification solutions, announced that a majority ... today approved the sale of the company,s Law Enforcement ... voted, 98.6% were cast in favor and 1.2% were ...
... , , FALLS CHURCH, Va., Dec. 9 ... the American Association for Laboratory Accreditation awarded the International ... the company,s Test Lab, which is part of the ... Lab is the second biometrics test laboratory in the ...
... GAINESVILLE, Fla. When treating devastating brain diseases such ... bags to find something to help a patient. But ... vast majority of patients with ataxia disabling disorders that ... Florida neurologists are trying to change that with the help ...
Cached Biology News:BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2UF to lead national effort to help patients with rare brain disease 2UF to lead national effort to help patients with rare brain disease 3